ArriVent BioPharma (AVBP) Expected to Announce Earnings on Monday

ArriVent BioPharma (NASDAQ:AVBP) will likely be posting its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect ArriVent BioPharma to post earnings of ($0.87) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 5, 2026 at 9:30 AM ET.

ArriVent BioPharma Stock Down 1.1%

Shares of AVBP stock opened at $22.97 on Friday. The firm has a 50 day moving average of $21.95 and a two-hundred day moving average of $20.71. The stock has a market capitalization of $948.20 million, a PE ratio of -5.42 and a beta of 1.02. ArriVent BioPharma has a 52 week low of $15.47 and a 52 week high of $26.00.

Institutional Trading of ArriVent BioPharma

Several institutional investors and hedge funds have recently made changes to their positions in AVBP. Infinitum Asset Management LLC increased its position in ArriVent BioPharma by 6.6% during the fourth quarter. Infinitum Asset Management LLC now owns 4,123,923 shares of the company’s stock worth $82,973,000 after buying an additional 255,000 shares during the period. Suvretta Capital Management LLC grew its position in shares of ArriVent BioPharma by 10.9% during the fourth quarter. Suvretta Capital Management LLC now owns 4,106,035 shares of the company’s stock worth $82,613,000 after acquiring an additional 402,583 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of ArriVent BioPharma by 36.8% in the 3rd quarter. Vanguard Group Inc. now owns 2,029,531 shares of the company’s stock valued at $37,445,000 after acquiring an additional 545,991 shares during the period. State Street Corp raised its position in ArriVent BioPharma by 6.3% in the 4th quarter. State Street Corp now owns 1,091,980 shares of the company’s stock valued at $21,971,000 after purchasing an additional 64,352 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in ArriVent BioPharma by 5.2% during the 4th quarter. Geode Capital Management LLC now owns 753,519 shares of the company’s stock worth $15,164,000 after purchasing an additional 37,231 shares during the period. 9.48% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently issued reports on AVBP. Cantor Fitzgerald began coverage on ArriVent BioPharma in a research note on Monday, December 22nd. They issued an “overweight” rating on the stock. Zacks Research upgraded shares of ArriVent BioPharma from a “strong sell” rating to a “hold” rating in a research note on Friday, December 5th. Citigroup lowered their price target on shares of ArriVent BioPharma from $33.00 to $31.00 and set a “buy” rating for the company in a report on Tuesday, November 11th. Weiss Ratings restated a “sell (d-)” rating on shares of ArriVent BioPharma in a report on Wednesday, January 21st. Finally, Truist Financial initiated coverage on shares of ArriVent BioPharma in a research report on Tuesday, November 25th. They set a “buy” rating and a $43.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $40.00.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.